Literature DB >> 15221598

Correlation and expression of p53, HER-2, vascular endothelial growth factor (VEGF), and e-cadherin in a high-risk breast-cancer population.

Eugene M Howard1, Stephen K Lau, Robert H Lyles, George G Birdsong, Talaat S Tadros, Jay N Umbreit, Ruby Kochhar.   

Abstract

BACKGROUND: Many genetic traits common to aggressive breast carcinoma have been identified; yet little is known about the interrelationships of such traits during tumor development, especially in women prone to aggressive cancer. This study examined the expression of four biological markers associated with poor prognosis at each stage of breast cancer progression in primary tumors from women of lower economic status and assessed the relationship between these markers.
METHODS: Archived primary breast tumors from 77 patients were assessed by immunohistochemical analysis for expression of human epidermal growth receptor 2 (HER-2), p53, vascular endothelial growth factor (VEGF), and e-cadherin, and the relationships between the expressions of these molecules were studied.
RESULTS: Twenty-two (29%) patients had advanced (stage III or IV) disease. HER-2, VEGF, e-cadherin, and p53 signal were positive for 31 (40%), 58 (75%), 63 (82%), and 37 (48%) of patients, respectively. Among the markers tested, only p53 exhibited a significant association between expression and stage of the disease ( P = 0.012). Expression of e-cadherin was positively associated with HER-2 overexpression ( P = 0.004), and high levels of HER-2 occurred with strongly positive e-cadherin tumors. Marginally significant positive associations were observed between HER-2 and p53 signal ( P = 0.06), and between disease stage and e-cadherin expression ( P = 0.08).
CONCLUSION: The significant tendency toward expression of e-cadherin in conjunction with HER-2 overexpression in breast cancer is a novel finding. The association of p53 with more advanced stages of cancer emphasizes it as a key participant in metastatic processes in breast cancer. Many genetic traits common to aggressive breast carcinoma have been identified; yet little is known about the interrelationships of such traits during tumor development, especially in women prone to aggressive cancer. This study examined the expression of four biological markers associated with poor prognosis at each stage of breast cancer progression in primary tumors from women of lower economic status and assessed the relationship between these markers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15221598     DOI: 10.1007/s10147-004-0386-4

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  7 in total

1.  Abrogation of p53 function leads to metastatic transcriptome networks that typify tumor progression in human breast cancer xenografts.

Authors:  Antonino B D'Assoro; Alexey Leontovich; Angela Amato; Jennifer R Ayers-Ringler; Cosima Quatraro; Kari Hafner; Robert B Jenkins; Massimo Libra; James Ingle; Franca Stivala; Evanthia Galanis; Jeffrey L Salisbury
Journal:  Int J Oncol       Date:  2010-11       Impact factor: 5.650

2.  HER2/ErbB2-induced breast cancer cell migration and invasion require p120 catenin activation of Rac1 and Cdc42.

Authors:  Emhonta Johnson; Darcie D Seachrist; Carlos M DeLeon-Rodriguez; Kristen L Lozada; John Miedler; Fadi W Abdul-Karim; Ruth A Keri
Journal:  J Biol Chem       Date:  2010-07-01       Impact factor: 5.157

3.  Risk factors for central nervous system metastasis in patients with metastatic breast cancer.

Authors:  Canfeza Sezgin; Erhan Gokmen; Mustafa Esassolak; Necmettin Ozdemir; Erdem Goker
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

4.  An immunohistochemically positive E-cadherin status is not always predictive for a good prognosis in human breast cancer.

Authors:  P Querzoli; D Coradini; M Pedriali; P Boracchi; F Ambrogi; E Raimondi; R La Sorda; R Lattanzio; R Rinaldi; M Lunardi; C Frasson; F Modesti; S Ferretti; M Piantelli; S Iacobelli; E Biganzoli; I Nenci; S Alberti
Journal:  Br J Cancer       Date:  2010-11-09       Impact factor: 7.640

Review 5.  How VEGF-A and its splice variants affect breast cancer development - clinical implications.

Authors:  Hivin Al Kawas; Inas Saaid; Paul Jank; Christina C Westhoff; Carsten Denkert; Therese Pross; Karoline Barbara Stephanie Weiler; Maria Margarete Karsten
Journal:  Cell Oncol (Dordr)       Date:  2022-03-18       Impact factor: 7.051

6.  CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer.

Authors:  José Roberto F Caldeira; Erika C Prando; Francisco C Quevedo; Francisco A Moraes Neto; Cláudia A Rainho; Silvia R Rogatto
Journal:  BMC Cancer       Date:  2006-03-02       Impact factor: 4.430

7.  Real time PCR analyses of expression of E-cadherin, alpha-, beta- and gamma-catenin in human breast cancer for predicting clinical outcome.

Authors:  Amit Goyal; Tracey A Martin; Robert E Mansel; Wen G Jiang
Journal:  World J Surg Oncol       Date:  2008-06-11       Impact factor: 2.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.